During a live event, Matthew Galsky, MD discussed neoadjuvant and adjuvant options for a patient case including nivolumab or ...

New findings on radiation plus adjuvant chemotherapy in patients with intermediate-risk cervical cancer seem to spell the end for the dual therapy in this group. Results from a phase 3 clinical tr ...

The rate of appropriate treatment suggestions was 86.6% for Claude3-Opus, 85.7% for GPT4-Turbo, and 75.0% for LLaMa3-70B. Artificial intelligence (AI) can accurately suggest appropriate adjuvant ...

Results from a meta-analysis suggest patients with resectable dMMR/MSI-H gastric cancer can forgo perioperative chemotherapy.

The European Commission (“EC”) granted marketing approval to AbbVie’s Rinvoq for treating giant cell arteritis (“GCA”), an ...

Chemotherapy plus local therapy improved overall survival and disease-free survival when compared to local therapy alone.

Adjuvant chemoradiation with weekly cisplatin ... but prior clinical data has indicated that adding chemotherapy could potentially improve outcomes in this population, lead author Sang Young ...

The FDA has approved neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab after radical cystectomy in MIBC.

EU approves AstraZeneca’s Imfinzi-in combo with chemotherapy to treat patients with resectable non-small cell lung cancer ...

Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone ...

The EC has approved Daiichi Sankyo and AstraZeneca’s Enhertu for use as a single agent to treat adults with certain breast ...